The ITFG1 Knockout SK-HEP-1 Polyclonal Cells product provides a precisely edited population of human hepatic sinusoidal endothelial cells in which the ITFG1 gene has been disrupted using CRISPR/Cas9 technology. This polyclonal knockout cell pool, derived from the SK-HEP-1 host line, enables loss-of-function studies of the ITFG1 immunomodulatory protein in a physiologically relevant liver endothelial context. As a mixed population of gene-edited cells, it preserves functional heterogeneity while abrogating target gene expression, facilitating robust investigations into ITFG1-mediated signaling and adhesion mechanisms without the constraints of clonal selection. Researchers can utilize this model to dissect the dual roles of ITFG1 in immune regulation and cell-matrix interactions directly in cells that mimic liver sinusoidal endothelial functions.
SK-HEP-1 cells were originally established from the ascites of a patient with adenocarcinoma of the liver and have since been characterized as an endothelial-like cell line displaying hallmark features of hepatic sinusoidal endothelial cells. These cells support filtration and endocytosis, participate in antigen presentation, and regulate leukocyte adhesion and transmigration, making them an invaluable in vitro model for liver sinusoidal biology. The endothelial nature of SK-HEP-1 cells is underscored by their expression of endothelial markers and their capacity to engage immune cells, providing a platform to study hepatic immune surveillance and tumor microenvironment interactions. This background is particularly relevant for investigating ITFG1, a molecule implicated in both T cell regulation and integrin-mediated adhesion.
ITFG1 functions as a critical negative regulator of T cell activation and proliferation downstream of the T cell receptor (TCR) and CD28 co-stimulatory signals. Mechanistically, TCR/CD3 complex engagement triggers a signaling cascade involving ZAP-70, LAT, and PLC??1, which normally leads to NFAT and NF-kB activation and subsequent cytokine production. ITFG1 is recruited to this signaling network and dampens the response by interacting with the SHP-1 phosphatase, which dephosphorylates key intermediates, thereby attenuating downstream targets such as NFAT and NF-kB. Additionally, ITFG1 interacts directly with integrin beta1 to modulate cell adhesion and migration, influencing processes such as leukocyte trafficking and tumor cell dissemination. Upstream regulators include TCR stimulation, CD28 co-stimulation, and IL-2, while downstream effects involve reduced cytokine secretion and altered integrin-mediated signaling.
In the SK-HEP-1 hepatic endothelial context, knockout of ITFG1 provides a powerful model to dissect the interplay between immune regulation and endothelial adhesion. Loss of ITFG1 is expected to enhance T cell activation parameters and alter integrin-dependent adhesion, thereby impacting leukocyte transmigration across the liver sinusoidal endothelium. This model is particularly relevant for investigating the molecular mechanisms underlying immune checkpoint regulation and peripheral tolerance maintenance in the liver, an organ known for its tolerogenic microenvironment. Furthermore, the endothelial origin of SK-HEP-1 cells allows exploration of how ITFG1 may contribute to hepatocellular carcinoma progression by modulating immune cell infiltration and tumor cell adhesion within the hepatic sinusoid.
This ITFG1 knockout cell pool is suited for a wide range of experimental applications, including the study of T cell regulation in autoimmunity, the role of ITFG1 in liver endothelial immune surveillance, and the modeling of hepatocellular carcinoma interactions. Representative assays that can be performed with this model include western blotting to confirm loss of ITFG1 and assess SHP-1 interaction, RT-qPCR for immune-related gene expression, flow cytometry to quantify adhesion molecules, T cell proliferation assays to evaluate functional consequences, co-immunoprecipitation to probe ITFG1?CSHP-1 complexes, migration and invasion assays to measure cell motility, luciferase reporter assays for NFAT or NF-kB activity, and ELISA for cytokine secretion. Drug target validation studies for immunomodulatory therapies can also be conducted. For additional technical details or custom inquiries, please contact Ascent Research.
